Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Palliative Care 2Nivolumab 2Methods 2Ipilimumab 2CTLA-4 Antigen 2Biopsy 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1pembrolizumab 1peginterferon alfa-2a 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × PLX8394 × Other hematologic neoplasm × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡